Global pharmaceutical company Cipla announced a joint venture of its European subsidiary with Shanghai-based Jiangsu Acebright Pharmaceutical for manufacturing respiratory products in China.
The joint venture company will be in the business of manufacturing, selling and distribution of pharmaceutical products, research and development services, analytical development services with the purpose of providing high quality and affordable drugs.
"As per the agreement, Cipla EU will hold 80 per cent stake and Acebright will hold 20 per cent stake in the joint venture company. Cipla EU's investment is estimated up to 24 million dollars over a period of four years," the company said in a statement.
"The joint venture company will become a related party upon incorporation and first tranche of investment. Any investments in joint venture company will be a related party transaction. None of the persons belonging to promoter or the promoter group of the company has any interest in the transaction," it added.
Cipla has presence in the United States and South Africa. The company is ranked ninth largest company by number of prescription in the US market.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app